TABLE 2.
Costs in Study Perioda
| PSP Cohort | Non-PSP Cohort | P Valueb | |
|---|---|---|---|
| Number of patients | 1,134 | 1,134 | – |
| Total costs (medical + drug), $ | 62,421 ± 73,221 (51,202) | 68,706 ± 82,701 (52,223) | 0.056 |
| Medical costs, $c | |||
| Overall | 25,074 ± 63,087 (8,544) | 35,419 ± 74,704 (11,053) | < 0.001 |
| Emergency department | 6,227 ± 39,405 (0) | 9,875 ± 44,277 (0) | 0.038 |
| Inpatient | 3,687 ± 18,589 (0) | 7,799 ± 40,437 (0) | 0.002 |
| Physician | 4,658 ± 13,502 (2,537) | 4,294 ± 5,954 (2,800) | 0.407 |
| Outpatient | 9,272 ± 22,648 (3,077) | 12,543 ± 22,677 (4,190) | < 0.001 |
| Other | 1,230 ± 8,743 (0) | 908 ± 5,094 (0) | 0.285 |
| Disease-related medical costs, $c,d | |||
| Overall | 10,162 ± 39,068 (1,698) | 15,511 ± 50,605 (1,974) | 0.005 |
| Emergency department | 4,093 ± 31,255 (0) | 5,365 ± 31,043 (0) | 0.331 |
| Inpatient | 2,008 ± 13,917 (0) | 5,064 ± 32,141 (0) | 0.003 |
| Physician | 1,428 ± 9,045 (697) | 1,455 ± 3,406 (685) | 0.925 |
| Outpatient | 2,348 ± 7,133 (145) | 3,398 ± 9,132 (194) | 0.002 |
| Other | 284 ± 4,314 (0) | 229 ± 4,003 (0) | 0.751 |
| Drug costs, $e | |||
| Overall | 37,347 ± 30,047 (38,936) | 33,287 ± 31,166 (28,681) | 0.002 |
| Disease-related (biologics and synthetic-targeted immune modulators)f | 32,315 ± 27,539 (34,829) | 28,347 ± 26,705 (23,775) | < 0.001 |
| Adalimumab | 27,335 ± 23,206 (25,457) | 21,905 ± 21,729 (16,527) | < 0.001 |
| Other biologics and synthetic-targeted immune modulators | 4,980 ± 17,469 (0) | 6,442 ± 18,618 (0) | 0.054 |
Data source: Symphony Health Solutions claims database, 2015-2017.
Note: All data are expressed as mean ± SD (median).
aCosts were evaluated over the 12-month period following the index date and were calculated using the service charge for medical claims and the primary plan payment for prescriptions.
bPSP cohort versus non-PSP cohort.
cExcluding biologic and synthetic-targeted immune modulator drug costs.
dIncludes costs from medical claims with a corresponding diagnosis of an autoimmune disease indication for each patient.
eIncluding biologic and synthetic-targeted immune modulator drugs covered by medical and pharmacy benefits, and any other prescription costs.
fIncluding abatacept, anakinra, apremilast, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, natalizumab, rituximab, secukinumab, tocilizumab, tofacitinib, ustekinumab, and vedolizumab.
PSP = patient support program; SD = standard deviation.